<?xml version="1.0" encoding="UTF-8"?>
<p>According the WHO, the use of blood components can be exceptionally therapeutic, but the use of blood components, especially platelets, should be limited to 22–50% of adult patients in various settings; additionally, blood transfusion in dengue is polemic and about 22–23% of are considered inappropriate [
 <xref rid="pone.0219287.ref006" ref-type="bibr">6</xref>, 
 <xref rid="pone.0219287.ref007" ref-type="bibr">7</xref>]. Thus, research that contributes to patient safety programmes are necessary to implement measures to reduce risks and mitigate side effects [
 <xref rid="pone.0219287.ref008" ref-type="bibr">8</xref>]. The economic impact studies of inappropriate blood components transfusions in dengue is scarce, and the urgency of these studies to fill information gap is clear [
 <xref rid="pone.0219287.ref009" ref-type="bibr">9</xref>, 
 <xref rid="pone.0219287.ref010" ref-type="bibr">10</xref>].
</p>
